Advertisement
Australia markets closed
  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     
  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     
  • AUD/USD

    0.6612
    +0.0040 (+0.61%)
     
  • OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD

    2,310.10
    +0.50 (+0.02%)
     
  • Bitcoin AUD

    95,350.46
    +5,447.26 (+6.06%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • AUD/EUR

    0.6140
    +0.0020 (+0.33%)
     
  • AUD/NZD

    1.0992
    -0.0017 (-0.16%)
     
  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     
  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why This 1 Growth Stock Should Be On Your Watchlist

Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

ADVERTISEMENT

Lantheus Holdings (LNTH)

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. It classifies its products into three categories — Precision Diagnostics (30.1% of FY23 revenues, up 9.4% from FY22), Radiopharmaceutical Oncology (65.9%, up 60.8%), and Strategic Partnerships and Other Revenue (4%, up 10.7%).

LNTH is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 5.5% year-over-year for the current fiscal year, with sales growth of 10.6%.

Two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.13 to $6.57 per share for 2024. LNTH boasts an average earnings surprise of 14.8%.

Lantheus Holdings is also cash rich. The company has generated cash flow growth of 54.5%, and is expected to report cash flow expansion of 41.9% in 2024.

Investors should take the time to consider LNTH for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research